{"id":"NCT01354145","sponsor":"Bioiberica","briefTitle":"Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI","officialTitle":"Twenty-four Month Exploratory Study of the Effect of Chondroitin Sulphate on Structural Changes in Knee Osteoarthritis Patients as Assessed by MRI","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2014-09","completion":"2014-10","firstPosted":"2011-05-16","resultsPosted":"2016-08-19","lastUpdate":"2016-08-19"},"enrollment":194,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Knee Osteoarthritis"],"interventions":[{"type":"DRUG","name":"Chondroitin sulfate","otherNames":["Condrosan"]},{"type":"DRUG","name":"Celecoxib","otherNames":[]}],"arms":[{"label":"Chondroitin sulfate (Condrosan)","type":"EXPERIMENTAL"},{"label":"Celecoxib","type":"ACTIVE_COMPARATOR"}],"summary":"The main purpose of this study is to compare the cartilage volume loss at the Baseline visit and after 24 months of treatment in patients treated with CHONDROITIN SULPHATE (CONDROSAN) 1200 mg daily vs. patients treated with CELECOXIB 200 mg daily.","primaryOutcome":{"measure":"Cartilage Volume Loss of the Lateral Compartment","timeFrame":"12 months (Day 364) and 24 months (Day 728)","effectByArm":[{"arm":"Chondroitin Sulfate (Condrosan)","deltaMin":6408,"sd":97},{"arm":"Celecoxib (Celebrex)","deltaMin":6196,"sd":97}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":22},"locations":{"siteCount":5,"countries":["Canada"]},"refs":{"pmids":["28728606","27809891"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":97},"commonTop":["Infections and infestations","Musculoskeletal and connective tissue disorders","Gastrointestinal disorders","Nasopharyngitis","Injury, poisoning and procedural complications"]}}